New Market Study, "Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) - Pipeline Review, H2 2013", Has Been Published
Global Markets Direct's, 'Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Mucopolysaccharidosis I (MPS I) (Hurler Syndrome), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Mucopolysaccharidosis I (MPS I) (Hurler Syndrome). Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) - Pipeline Review, Half Year is built using...
View full press release